Moreover, these studies demonstrated that increased levels of ERα predicted better survival, suggesting that this receptor may be of diagnostic significance and that estrogen could be a novel therapeutic for targeting HPV+HNSCC (20, 21). The gene discussed is ESR1; the disease is head and neck squamous cell carcinoma.